Stage as the Sole “Biomarker” for Adjuvant Pembrolizumab in Resected Stage IB to IIIA NSCLC without Considerations for PD-L1 Expression Level, ALK/EGFR Mutational Status, and Prior Adjuvant Chemotherapy per FDA Approval Indications of PEARLS/Keynote-091?

Stage as the Sole “Biomarker” for Adjuvant Pembrolizumab in Resected Stage IB to IIIA NSCLC without Considerations for PD-L1 Expression Level, ALK/EGFR Mutational Status, and Prior Adjuvant Chemotherapy per FDA Approval Indications of PEARLS/Keynote-091?

Misako Nagasaka,1– 3 Saihong Ignatius Ou1,2 1University of California Irvine School of Medicine, Orange, CA, USA; 2Chao Family Comprehensive Cancer Center, Orange, CA, USA; 3Division of Neurology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, JapanC...

Full description

Bibliographic Details
Main Authors: Nagasaka M, Ou SI
Format: Article
Language:English
Published: Dove Medical Press 2023-12-01
Series:Lung Cancer: Targets and Therapy
Subjects:
post operative therapy
checkpoint inhibitors
atezolizumab
impower010
biomarker
Online Access:https://www.dovepress.com/stage-as-the-sole-biomarker-for-adjuvant-pembrolizumab-in-resected-sta-peer-reviewed-fulltext-article-LCTT

Internet

https://www.dovepress.com/stage-as-the-sole-biomarker-for-adjuvant-pembrolizumab-in-resected-sta-peer-reviewed-fulltext-article-LCTT

Similar Items